Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
219 institutional managers reported holding CLDX in 13F filings for the quarter ended 2026-03-31. 51 opened new positions that quarter. Held by Wellington Management, BlackRock, Vanguard Group, among others. On the short side, 7.3M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (9.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CLDX's share count grew 66.6% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at CLDX over the trailing three years: 2024: 1 buy totaling $308k. 6 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CLDX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2022-03-01 | +4.7% | -2.0% |
| 2022-05-06 | -10.3% | -7.3% |
| 2022-08-09 | -3.8% | -16.9% |
| 2022-11-10 | +9.4% | +25.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CLDX's latest 8-K filings: 2026-07-15 (items 5.02, 9.01); 2026-06-26 (items 5.02, 5.07, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-04-02 (items 1.01, 8.01, 9.01); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.